MedTrace Logo

RP-6306 in Patients With Advanced Cancer

NCT05605509 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 28

Last updated 2026-02-06

No results posted yet for this study

Summary

This study is being done to answer the following questions:

* Is the new drug, RP-6306, safe to use, and what effects does it have on cancer when given with standard treatment?
* If there are specific biomarkers, do patients have an improved response to treatment compared to those without the biomarker?

This study is being done to find out if this approach is better or worse than the usual approach for this type of cancer. The usual approach is defined as care most people get for this type of cancer.

Conditions

Interventions

DRUG

Trastuzumab

standard doses q3weekly

DRUG

RP-3500

Dose and schedule will be assigned at enrolment

DRUG

RP-6306

Dose and schedule will be assigned at enrolment

DRUG

Gemcitabine

Dose and schedule will be assigned at enrolment

DRUG

FOLFIRI Protocol

Irinotecan Leucovorin FU

Sponsors & Collaborators

  • Repare Therapeutics

    collaborator INDUSTRY

  • Canadian Cancer Trials Group

    lead NETWORK

Principal Investigators

  • Stephanie Lheureux · University Health Network, Princess Margaret Hospital, Toronto ON Canada

  • Yvette Drew · BCCA-Vancouver Cancer Centre, Vancouver BC Canada

  • Eric Chen · University Health Network, Princess Margaret Hospital, Toronto ON Canada

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-05-24
Primary Completion
2025-11-14
Completion
2026-02-05

Countries

  • Canada

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05605509 on ClinicalTrials.gov